An 83-year-old woman with severe Alzheimer’s. For years. She spoke in monosyllables. Barely moved. Lost control of her bladder. Then she took psilocybin. And talked again.
Not just talked. Initiated conversations. Remembered things. Smiled with actual animation in her face. It happened after a massive dose of magic mushrooms. The kind of detail that makes neuroscience journals blink twice.
“It feels good to come here.”
Those were her words. Spoken during a follow-up session. Marcus Lago runs the Ankh Cross Association in São Paul o, a holistic medicine group. He watched this shift unfold. He saw her move with agility that had been absent for years. Eye contact held longer. Shoulders relaxed. It was dramatic.
She hadn’t changed overnight, exactly. The timeline was messy, real life messy.
Here is the setup: Ten years post-diagnosis. Half that time spent in severe functional decline. With her son’s permission, she took 5 grams of Enigma strain Psilocybe cubensis. Oral. Potent. She sweated heavily. Slumped into a sleep-like haze that lasted hours. Nineteen hours later. The ice broke. She spoke for four hours straight. Reflected on memories.
Then came the days and weeks. This is where the physical changes stacked up. She dressed herself. Picked out coordinating outfits. Recognized a rented car. Noticed when people were missing. Her bladder control returned. Periods of incontinence that had become routine vanished. About a month after the first dose. She got 3 grams more. Talked about surfing on a peaceful island with her son.
Alzheimer’s doesn’t just turn off. The damage is there. The team stresses this point. The disease wasn’t cured. But something latent woke up. Residual capacity, perhaps. Psilocybin hits serotonin receptors. It likely boosted neuroplasticity. Changed how brain networks talk to each other.
David Nutt from Imperial College London hears similar stories. Often from the fringe. Sometimes from clinical edges. “These accounts don’t promote longevity,” he says. “But they fit the known anti-inflammatory activity of the drugs.”
Think of the brain like a crowded room where some voices shout others down. Amyloid clumps. Tau tangles. Inflammation. Cell death. The leading theory on Alzheimer’s involves these structural failures. But circuits also suppress each other. Nutt suggests psychedelics might break those suppressions. Unlock a locked door.
Of course. Not everyone is cheering.
Albert Garcia-Romeu at Johns University has a litany of concerns. He studies psilocybin for depression in mild cognitive impairment. He calls the report ethically shaky. Scientifically thin. The dose? Huge. Five grams is high. Followed by three. Medical wisdom usually says “low and slow.” Where was the taper? Where was the safety ramp?
And how long did it last? The paper stops looking after one month. That is a snapshot. Not a movie. Maybe the fog returned. Maybe not. We don’t know.
Garcia-Romeu also points to the diagnosis itself. Symptoms only. No biomarkers. No neuroimaging verification. One case study cannot become a prescription. You cannot extrapolate hope from a single anecdote. The field demands rigor. This feels like a near-miss with standard care.
Still. Rudolph Tanzi from Harvard sees the spark. He admits the limitations. One person. No control group. But the shift was dramatic. Too dramatic to ignore entirely.
“We have to be careful not to draw conclusions,” Tanzi says. “But it suggests a trial might be warranted.”
Carefully. Ethically. With documentation that actually holds up to scrutiny. The potential is there. It hums beneath the surface of neurology right now. But the road from “magic” to “medicine” is paved with caution.
For this woman. It worked. For the field. The question mark hangs in the air. Unanswered.
